Drug Trial Radar · NCT06380751
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
788
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Dec 18, 2029
Study completion Dec 30, 2031
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer
Conditions
- Advanced Breast Cancer
Interventions
Saruparib (AZD5305)Drug
Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
CamizestrantDrug
Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
AbemaciclibDrug
CDK4/6 Inhibitor
RibociclibDrug
CDK4/6 Inhibitor
PalbociclibDrug
CDK 4/6 Inhibitor
FulvestrantDrug
Endocrine Therapy
LetrozoleDrug
Endorcine Therapy
AnastrozoleDrug
Endocrine Therapy
ExemestaneDrug
Endocrine Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (Arm 1 vs arm 2)Time frame: Up to approximately 64 months
Locations
306 sites in 29 countries. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona · Recruiting
Research Site
Fountain Valley, California · Recruiting
Research Site
Glendale, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Newport Beach, California · Recruiting
Research Site
Aurora, Colorado · Recruiting
Research Site
Grand Junction, Colorado · Withdrawn
Research Site
Hollywood, Florida · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Orlando, Florida · Withdrawn
Research Site
Orlando, Florida · Not yet recruiting
Research Site
Arlington Heights, Illinois · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Evanston, Illinois · Recruiting
Research Site
Park Ridge, Illinois · Withdrawn
Research Site
Schaumburg, Illinois · Not yet recruiting
Research Site
Urbana, Illinois · Recruiting
Research Site
Winfield, Illinois · Recruiting
Research Site
Indianapolis, Indiana · Withdrawn
Research Site
Louisville, Kentucky · Withdrawn
Research Site
Baltimore, Maryland · Recruiting
Research Site
Silver Spring, Maryland · Withdrawn
Research Site
Silver Spring, Maryland · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Dearborn, Michigan · Withdrawn
Research Site
Detroit, Michigan · Withdrawn
Research Site
Royal Oak, Michigan · Withdrawn
Research Site
Royal Oak, Michigan · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Saint Joseph, Missouri · Recruiting
Research Site
Springfield, Missouri · Recruiting
Research Site
St Louis, Missouri · Not yet recruiting
Research Site
Camden, New Jersey · Recruiting
Research Site
New Brunswick, New Jersey · Withdrawn
Research Site
Brooklyn, New York · Withdrawn
Research Site
Mineola, New York · Recruiting
Research Site
New Hyde Park, New York · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Withdrawn
Showing 40 of 306 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.